This research report is a separate document:
中国生物科技服务(8037)：22年二季度业绩增长保持强劲
China Biotech Services (8037): Performance growth remained strong in the second quarter of '22
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.